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Abstract
Background:  Atrial fibrillation (AF) is an important independent risk factor for stroke.
Randomised controlled trials have shown that this risk can be reduced substantially by treatment
with warfarin or more modestly by treatment with aspirin. Existing trial data for the effectiveness
of warfarin are drawn largely from studies in selected secondary care populations that under-
represent the elderly.
The Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study will provide evidence of
the risks and benefits of warfarin versus aspirin for the prevention of stroke for older people with
AF in a primary care setting.
Study design: A randomised controlled trial where older patients with AF are randomised to
receive adjusted dose warfarin or aspirin. Patients will be followed up at three months post-
randomisation, then at six monthly intervals there after for an average of three years by their
general practitioner. Patients will also receive an annual health questionnaire.
1240 patients will be recruited from over 200 practices in England. Patients must be aged 75 years
or over and have AF. Patients will be excluded if they have a history of any of the following
conditions: rheumatic heart disease; major non-traumatic haemorrhage; intra-cranial haemorrhage;
oesophageal varices; active endoscopically proven peptic ulcer disease; allergic hypersensitivity to
warfarin or aspirin; or terminal illness. Patients will also be excluded if the GP considers that there
are clinical reasons to treat a patient with warfarin in preference to aspirin (or vice versa).
The primary end-point is fatal or non-fatal disabling stroke (ischaemic or haemorrhagic) or 
significant arterial embolism. Secondary outcomes include major extra-cranial haemorrhage, death 
(all cause, vascular), hospital admissions (all cause, vascular), cognition, quality of life, disability and 
compliance with study medication.
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Background
Atrial fibrillation (AF) is associated with a 50% to 90%
increase in all cause mortality, principally due to excess
risk of death from cardiovascular diseases including stroke
[1,2]. It is a particularly important risk factor for stroke in
the elderly, since both the incidence of stroke and the
prevalence of AF rise with age [3,4]. Whilst AF is associ-
ated with 15% of all strokes, it is associated with 36% of
strokes in people over the age of 80 [5]. It is important,
therefore, to identify the most effective strategy for stroke
prevention for older people with AF.
Four major strategies have been tested in clinical trials to
reduce stroke risk in AF including the use of: adjusted-
dose warfarin; anti-platelet agents such as aspirin; fixed
low dose warfarin and fixed low dose warfarin in combi-
nation with aspirin. Previous studies have shown that
both fixed low dose warfarin and the combination of low
dose warfarin with aspirin are significantly less effective
than adjusted dose warfarin. [6–9] The principal alterna-
tives to reduce stroke risk in patients with AF are therefore
adjusted dose warfarin or aspirin.
There is strong evidence that adjusted dose warfarin is
highly effective in reducing risk of stroke and thrombo-
embolism in people with non-rheumatic AF [10–12]. A
meta-analysis of five trials of warfarin therapy suggested
that this approach results in a 68% reduction in risk of
stroke [10]. An important side effect of warfarin is haem-
orrhage, but under trial conditions, observed rates of seri-
ous haemorrhage have been low [10]. Aspirin appears to
be a safer, but less effective alternative to warfarin result-
ing in a 22% reduction in risk of stroke [12,13].
A summary of the seven trials which have directly com-
pared antiplatelet agents to warfarin for stroke prevention
in AF in the relevant age group (where possible) is shown
in table 1. While three studies [6,14,15] found significant
benefits of adjusted dose warfarin over aspirin of the order
of magnitude that would be anticipated from the indirect
comparisons, these findings were not replicated in the
other four studies. Indeed, two of the studies showed non-
significant results in favour of aspirin [8,16]. Published
meta-analyses of the trials have reached different conclu-
sions due, in part, to controversy [17] as to which trials
should be included in this review [12,18]. Notwithstand-
ing this issue, study populations of trials examining the
use of warfarin for patients in AF significantly under-rep-
resented elderly people. In excess of 50% of people in AF
in the community would be expected to be over the age of
75,[4] whilst only 20% of patients in the trials were in this
age group [10]. In the EAFT study, age was the main rea-
son patients were considered ineligible for the study,
accounting for 55% of exclusions [14]. As a result, the evi-
dence for the effectiveness of warfarin in AF for patients
over the age of 75 is much less impressive than the evi-
dence for patients under this age [19]. Sub-group analysis
of a review of five trials suggested that warfarin did reduce
stroke risk in this age group, but it was based on only 24
events [10].
There are also concerns over the safety, in terms of
increased haemorrhagic risk, of warfarin [18] and this
may be particularly important for older age groups. In the
SPAF II study, the annual risk of stroke with residual defi-
cit (haemorrhagic and ischaemic) was in fact slightly
higher (4.6% vs 4.3%) in patients aged over 75 assigned
to warfarin as opposed to aspirin [16]. Factors that might
increase risk of major haemorrhage in very elderly
patients on warfarin include: deficits in auditory and vis-
ual acuity; risk of falls; impaired cognition and memory;
dietary vitamin K deficiency; polypharmacy; amyloid
angiopathy; and occult gastro-intestinal lesions [19]. A
secondary analysis of the SPAF trial data, comparing
adjusted dose warfarin versus aspirin, found age to be an
important risk factor for major haemorrhage on warfarin
[20]. This association of age with risk of haemorrhage has
been found in some observational studies,[21,22] but not
others [23].
Finally, it is important that a trial performed to investigate
the role of anticoagulation in the elderly is carried out in
a primary care setting [24]. The existing evidence base for
the benefits of anticoagulation is comprised of trials that
were mostly conducted on hospital populations. General
practitioners (GPs) have questioned the applicability of
the results of these studies to primary care settings [25].
Patients were mostly recruited from hospital, and 3% to
40% of patients identified with AF were entered into the
trials. While many exclusions were legitimate (e.g. prior
indication for warfarin, or clear contra-indication), some
were less justifiable (for example about a third of patients
in the SPAF II study were excluded for reasons that may
have related to perceived haemorrhage risk). It is notewor-
thy that concerns over risk of haemorrhage were found to
be the main barrier to anticoagulant use by primary care
physicians in the USA [26]. If GPs assume that the risks of
haemorrhage in their practice are higher than was
observed in the trials, the perceived harm/benefit ratio for
individual patients is changed. Therefore, to improve the
likelihood that results of the proposed study are acted
upon, it is important that it is carried out in a setting
which is representative of primary care [24].
Overall, the limitations of the evidence base for manage-
ment of AF in elderly primary care population is reflected
in low uptake of anticoagulation in clinical practice.
Audits of use of warfarin in AF have consistently demon-
strated low uptake of the therapy, particularly in the eld-
erly. Recent studies based in defined UK general practiceBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/9
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populations have found that only between 18% and 40%
of people in AF without contra-indications for therapy
were being treated with warfarin. [27–29] Sudlow et al
found that only 17% of patients in AF over the age of 74
were on warfarin [30]. There is also no clinical consensus
with regard to use of anticoagulation in the elderly. In a
review of the content of guidelines on anticoagulant treat-
ment in AF in Great Britain, Thomson et al found that
between 13% and 100% of patients with AF would be
treated depending upon which guideline was used [31].
An important cause of this variation was different advice
with regard to age. Ten of 20 guidelines referred to the
higher risks of anticoagulation in the elderly, and eight
gave upper age limits, with four recommending not treat-
ing people over the age of 80, and two suggesting that
anticoagulation should be used in people over the age of
75 only in exceptional circumstances. If, as is current prac-
tice, the majority of patients over the age of 75 with AF are
not treated with warfarin, targeting this group of patients
is likely to have a substantial public health benefit in
terms of preventing stroke [32] if warfarin is indeed more
effective than aspirin.
In conclusion, although there is a good evidence basis to
support adjusted-dose warfarin as the most effective strat-
egy for the prevention of stroke in AF, there are limitations
when applying these data to older people (75 years or
over) and a trial focusing on this age group is needed [19].
The Birmingham Atrial Fibrillation Treatment of the Aged
Study (BAFTA) aims to provide robust data on the effec-
tiveness, in terms of stroke prevention and haemorrhagic
risk, of adjusted dose warfarin versus aspirin in older
patients with AF identified from primary care settings.
Methods
Study Aims
The primary aim of BAFTA is to compare the incidence of
fatal and non-fatal disabling stroke (ischaemic or haemor-
rhagic) and systemic embolism in older patients with AF
who are treated with either adjusted dose warfarin or
aspirin.
Table 1: Randomised controlled trials which have compared aspirin with adjusted dose warfarin in the treatment of atrial fibrillation
Study Population Age Interventions Primary end-point Relative risk of 
primary end-point 
(95% CI)
AFASAK I 
[15].                      
Primary care. N = 671 
(in relevant arms)
No age limits. 
Mean age 74 yrs.
3 arm study including 
warfarin (INR 2.8–4.2) and 
aspirin (75 mg).
Stroke, transient ischaemic 
attack and systemic 
embolus.
Not given. RR on 
warfarin as compared 
to aspirin or placebo: 
0.36
EAFT [14].                       TIA or minor stroke 
in preceding 3/12 N = 
455 (in relevant arms)
65% were >69 yrs 3 arm study, including 
anti-coagulant (INR 2.5–
4.0) and aspirin (300 mg).
Death from vascular 
disease; non-fatal stroke 
(including haemorrhage); 
non-fatal myocardial 
infarction or systemic 
embolus
0.60 (0.41 to 0.87)
SPAF II [ 1 6 ] .                        N   =   3 8 5 > 7 5   y r s W a r f a r i n  ( I N R   2 . 0 – 4 . 5 )   v s  
aspirin (325 mg).
Ischaemic stroke and 
systemic embolus
0.73 (0.37 to 1.5) 1.07 
(stroke with residual 
deficit including 
haemorrhagic)
AFASAK  II  [8].                                            Primary care. N = 339 
(in relevant arms)
No upper age 
limit. Mean age 73 
yrs.
3 arm study, including 
warfarin (INR 2.0–3.0) and 
aspirin (300 mg) arms.
Stroke (ischaemic or 
haemorrhagic) or systemic 
thrombo-embolus.
1.26 (intention to 
treat) 0.78 (treatment 
received analysis)
SIFA [43].                       Recent cerebral 
ischaemia N = 916
Age > 30 yrs Mean 
age 72 yrs.
Warfarin (INR 2.0–3.5) vs 
indobufen (200 mg bd or 
100 mg bd if creatinine 
clearance < 80 mls/min).
Stroke (including 
haemorrhagic), myocardial 
infarction, pulmonary 
embolus, systemic embolus 
or vascular death
0.85 (not significant)
SPAF III [ 6 ] .                        A t   l e a s t   1   r i sk   f a c t o r  
for stroke N = 1044
No upper age 
limit. Mean age 71 
yrs.
Warfarin (INR 2.0–3.0) vs 
aspirin (325 mg) and fixed 
mini-dose warfarin (INR 
1.2–1.5).
Ischaemic stroke and 
systemic embolus
0.26 (0.13 to 0.50)
PATAF [ 9] .                       P rim ar y ca r e. N = 27 2  
(in relevant arms)
Age 60–78. Mean 
age 70 yrs.
3 arm study including 
warfarin (INR 2.5–3.5) and 
aspirin (150 mg).
Stroke, systemic embolus, 
major haemorrhage or 
vascular death.
0.78 (0.34 to1.8)
[In the relative risk column, the risk of an end-point on variable dose warfarin is compared to the risk on aspirin (and fixed-minidose warfarin in the 
case of SPAF-III). Thus, a relative risk greater than one favours aspirin, and a relative risk less than one favours warfarin]BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/9
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Study design and setting
BAFTA is a primary-care based, pragmatic randomised
controlled trial where older people (aged 75 years or over)
with AF are randomised to receive either warfarin or aspi-
rin. The pathway by which patients are recruited is given
in figure 1. A full economic evaluation is also being
conducted.
Ethical considerations
Full ethical approval for this study has been obtained.
Two external bodies, a Data Monitoring and Ethics Com-
mittee and a Trial Steering Committee, will monitor study
progress.
Study interventions
Adjusted dose warfarin with a target international normal-
ised ratio (INR) of 2.5 (acceptable range of 2.0 to 3.0) was
selected as this is the recommended strategy of the British
Society of Haematology for the treatment of AF [33]. War-
farin dosage and INR monitoring may be carried out in
primary care or hospital clinics, depending on whichever
is the standard procedure for the participating practice.
Methods for adjusting warfarin dose and monitoring INR
are at the discretion of the local practices and hospital
anticoagulation clinics. Patients allocated aspirin will
receive 75 mg daily as this dose has been shown to be as
effective as higher doses (e.g. 300 mg) in the prevention
of stroke [34].
Identification of eligible patients
Eligible patients will be identified from general practices
in England selected mainly from the West Midlands.
Larger practices (three or more partners) will be recruited
in preference to smaller ones. Each practice will receive a
start-up visit by a member of the research team who will
run a practice-based computer search to identify all
patients aged 74 years or over. Within this population,
patients with probable AF will be identified in three ways:
by computerised searches of GP records; by opportunistic
screening of the pulse by practice staff and by considering
patients who present with previously undiagnosed AF
('incident cases').
The computerised note searches of general practice
records will be tailored towards the information held in
each practice and will identify patients who have already
been diagnosed as having AF. Patients in this group will
be invited to attend an ECG clinic at their practice. The
opportunistic screening will take place by placing a flag
(paper or computerised) in the case notes of all patients
aged 74 years or over who were not identified as being in
AF as a result of the computer searching. The flag prompts
a member of the primary health care team to take the
patient's pulse the next time the patient consults. It is
anticipated that over 12 months, 91% of patients in this
age range will have been seen at least once by their GP
[35]. Pulse palpation is a highly sensitive (though non-
specific) way of detecting AF (sensitivity = 94%) [36]. The
result of the pulse check (regular or irregular) is recorded
and those patients with an irregular pulse will be invited
to an ECG clinic.
Confirmation of diagnosis of AF: the ECG clinic
The practice nurse records a 12 lead ECG and collects
other baseline information (table 3) at a dedicated clinic.
The ECG is sent to the study team to be read by a cardiol-
ogist, who will report whether AF is present or absent and
list any other significant abnormalities. Where the ECG
shows sinus rhythm, but the patient has a case note diag-
nosis of AF, records of ECGs and relevant case notes over
the previous two years will be reviewed. If there is evi-
dence of chronic atrial fibrillation (permanent or paroxys-
mal) in the case records, including evidence of at least one
ECG in the last two years showing AF, then this patient
will be considered eligible. Cases where the AF appears
transient or self-limiting are excluded. Patients identified
as an incident case, who had an ECG outside the BAFTA
study, will have this ECG submitted to the BAFTA cardiol-
ogists for reading and do not need to be called to the ded-
icated nurse clinic.
Determining eligibility for the study
Eligibility for the study is determined in two stages. Firstly,
the practice nurse, in consultation with the GP, reviews
the patient's medical records to check whether the patient
satisfies the study inclusion criteria and does not have any
of the absolute exclusion criteria listed in table 2. Sec-
ondly, the GP decides whether there is clinical uncertainty
as to whether the patient should be treated with aspirin or
warfarin, taking into account other clinical factors (see
table 2, and randomisation clinic below). Eligible patients
are invited to a randomisation clinic appointment. All
patients will have received a detailed information sheet
about the BAFTA study before their randomisation clinic
appointment. Patients who are not eligible for a randomi-
sation clinic appointment are followed-up at the GP's
discretion.
Randomisation clinic
At the randomisation clinic the GP once again checks to
ensure that the patient satisfies both inclusion and abso-
lute exclusion criteria. Patients with temporary exclusion
criteria (table 2) are not eligible for the study, though may
be re-considered at a later date.
The decision as to whether or not the patient is eligible for
trial entry is made by the GP using the uncertainty princi-
ple. That is, if a GP is certain that a patient should not be
entered into the trial, for whatever reason, that patient is
not eligible for entry into BAFTA. If the GP is substantiallyBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/9
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Summary of trial design Figure 1
Summary of trial design. Incident case group: patient presents with atrial fibrillation to GP; Case note review group: patient is 
identified through GP computer system; Opportunistic screening group: patient is identified through opportunistic taking of pulse.
Incident case
group
Case note
review group
(CNR group)
Opportunistic
screening group
ECG
read by cardiologist
Case notes
reviewed for
ECG evidence of AF
(CNR group only)
Ineligible
Patient
not in AF
Adjusted dose
warfarin
target INR 2.5
Aspirin
75mg
Randomised
Patient eligible
and consents
Follow-up at
GP's discretion
Patient eligible but
refuses to take part
Patient attends
randomisation
clinic appoinment
Patient meets
inclusion criteria
and has no absolute
exclusion criteria
Follow-up at
GP's discretion
Patient not eligible
Patient fails either
inclusion &/or
exclusion criteria
Practice nurse
records
medical history
Patient in
AF
Patients aged
74 years or over
from 200 practicesBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/9
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uncertain whether or not warfarin is indicated, then the
patient is eligible for BAFTA. This decision will need to be
made on a case by case basis after consideration of all rel-
evant factors listed in table 2. Patients already on warfarin
or aspirin are eligible for consideration. In each case, fac-
tors which increase risk of haemorrhage (points 1 to 5)
need to be set against the high risk of stroke in these
patients, which is increased still further by certain factors
(point 6). If the GP remains uncertain as to whether or not
the patient should be on warfarin or aspirin, the patient
will be offered trial entry. Patients with substantial
cognitive impairments (defined as 10 or more on the
Short Orientation Memory Concentration test [37] or 8–
9 at the GP's discretion) can be considered for trial entry
as long as a carer from the patient's family is willing to
support the patient's entry into the trial, and the GP is sat-
isfied that warfarin could be safely administered.
If the patient (and carer where appropriate) is willing to
take part, the GP then obtains written consent from the
patient (and carer) prior to randomisation. The randomi-
sation will be stratified by age into three strata (75–79;
80–84; and 85+) with gender balanced by minimisation.
The randomisation schedule has been developed by an
independent trials unit, and the random allocation is
obtained by GPs telephoning this randomisation service.
Once the treatment allocation has been obtained, the GP
then prescribes the trial medication and arranges the
appropriate clinical follow up. Patients who are either
ineligible for trial entry or who do not wish to take part in
the study are treated at the discretion of the GP.
Patient follow-up procedures
Patients will be followed up from trial entry until the end
of the study (anticipated average: three years). Follow-up
is composed of several elements. First, at three months
post-randomisation and then six monthly intervals there
afterwards, the GP will review each patient and record evi-
dence of any primary or secondary end-points (listed in
table 3) and compliance with trial medication. Second, at
six monthly intervals but three months after the GP
review, a researcher will review the patient's medical
records and note whether or not primary and secondary
outcomes have occurred. Third, at twelve months post-
randomisation and annually there afterwards the patient
will be sent a postal health questionnaire (described in
table 3). Non-responders will be sent a second question-
naire within three weeks, and then contacted by
telephone if they fail to respond after two successive mail-
ings. The records of patients will be flagged at the NHS
Central Register to ensure that the study team is informed
about any deaths that occur. Finally, INR data for patients
on warfarin will be obtained from their hospital or GP
records.
Table 2: Study inclusion and exclusion criteria
Inclusion criteria
• Aged 75 years or over.
• Atrial fibrillation or flutter confirmed by a study ECG or ECG taken within 2 years of the practice start-up visit.
Absolute exclusion criteria
• Rheumatic heart disease.
• Major non-traumatic haemorrhage (e.g. gastro-intestinal).
• Intra-cranial haemorrhage.
• Oesophageal varices.
• Endoscopically proven peptic ulcer disease in previous year.
• Known allergic hypersensitivity to either of the study medications.
• Patient is known to be terminally ill.
Temporary exclusion criteria
• Uncontrolled hypertension (BP > 180 systolic or 110 diastolic). In such circumstances, the patient will be eligible once the hypertension has been 
brought under control.
• Recent surgery or head injury (i.e. in last three months). In such circumstances, patient will be eligible once three months had elapsed.
Other relevant factors
1. Poor memory / cognitive function which is defined here as a score of 10 or more on the short orientation-memory concentration test [37]. If the 
patient does not 'pass' this test, but has a carer who is responsible for the patient's medication, then they are eligible for the trial.
2. Alcohol dependency (30 units per week or more) or binge drinking (10 units at a time).
3. Poorly controlled epilepsy such that the patient is at significant risk of head injury.
4. Risk of falls likely to result in head injury.
5. Long term use of non-steroidal anti-inflammatory agents (NSAIDs). In this circumstance, patients who are on NSAIDs with a lower risk of gastro-
intestinal haemorrhage such as ibuprofen, diclofenac or naproxen [40]. are eligible. Given the risks associated with the long term use of NSAID 
therapy in older age people with atrial fibrillation, consideration should be given to changing patients to alternative medication, and then reviewing 
trial eligibility.
6. Factors known to increase risk of stroke in these patients: previous stroke or transient ischaemic attack, known heart failure, systolic BP greater 
than 150 mmHg or diabetes.BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/9
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Patient outcome measures
The criteria used to assess whether or not the patient is
suitable for inclusion in the study, and the primary and
secondary outcome measures assessed across the follow-
up period for patients randomised are summarised in
table 3.
The primary outcome is the incidence of fatal or non-fatal
disabling stroke (ischaemic or haemorrhagic), intra-cra-
nial haemorrhage or significant arterial embolism. A disa-
bling stroke is defined as a Rankin Score [3] of 2 to 5 one
month or more after stroke, or a deterioration in the score
if the baseline Rankin Score was greater than or equal to
2. If the stroke led to a hospital admission of 30 days or
more, this is also classified as a disabling stroke. Intra-cra-
nial haemorrhage will require verification through brain
imaging and includes sub-dural haemorrhage and sub-
arachnoid haemorrhage. Significant arterial embolism
also requires verification by vascular imaging, scintigra-
Table 3: Timing and content of study assessments
Identifying eligible patients: Baseline data
ECG clinic: practice nurse interview-administered schedule
• Socio-demographic characteristics:
Age, sex and ethnicity.
• Medical history:
Previous history of hypertension, stroke, transient ischaemic attack, diabetes, myocardial infarction, heart failure, angina, rheumatic fever, valvular 
heart disease, oesophageal varices, peptic ulcer disease or intra-cranial haemorrhage. Current prescription medications. Smoking status and alcohol 
intake.
• Clinical measures:
Blood pressure and a 12 lead ECG.
Receipt of ECG results: practice nurse & GP review of the medical record
• Medical history (for patients in atrial fibrillation only):
Previous history of hypertension, stroke, transient ischaemic attack, diabetes; myocardial infarction, heart failure, angina, rheumatic fever, valvular 
heart disease, oesophageal varices, peptic ulcer disease or intra-cranial haemorrhage. Current prescription medications.
Randomisation clinic
Patient schedule: self-completion
• Disability assessed by the Rankin Score [3].
• Health related quality of life assessed by the SF-12 [41] and EQ-5D. [38].
Practice nurse schedule: interview
• Blood pressure, current prescription medications and the Short-Orientation Memory Concentration test [37].
GP schedule: interview
• Review of inclusion and exclusion criteria and record outcome of consent process.
Patient follow-up procedures: for an average of three years
Obtaining information on patients who died
• Records flagged at NHS central register.
GP interviews at 3 months post-randomisation, then six monthly intervals there afterward
• Major extra-cranial haemorrhage (fatal, or one that requires transfusion or surgery).
• Death – all cause, all vascular and stroke.
• Admission to hospital – all cause, all vascular, stroke.
• Cognition assessed by Mini-Mental State Exam [42]. at (9, 21, and 33 month follow-ups only).
• Disability assessed by the patient using the Rankin Score [3].
• Blood pressure and apical pulse rate.
• Drop out/withdrawal from allocated medication.
Researcher case note review at 6 months post-randomisation, then six monthly intervals there afterward
• Major extra-cranial haemorrhage (fatal, or one that requires transfusion or surgery).
• Death – all cause, all vascular and stroke.
• Admission to hospital – all cause, all vascular, stroke.
• Drop out/withdrawal from allocated medication.
Patient self-completed postal questionnaire at 12 months post-randomisation, then annually there afterwards
• Disability assessed by the Rankin Score [3].
• Health related quality of life assessed by the SF-12 [41] and EQ-5D [38].
• Patient costs questionnaire (warfarin patients only, at 12 months).BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/9
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phy, surgery or autopsy. Pulmonary embolism is not
included as a primary outcome.
When a possible primary end-point is identified in the
study population, the hospital discharge summary, results
of brain imaging and a copy of the death certificate (if
applicable) will be obtained. These data will be scruti-
nised by two neurologists independently, blind to the
treatment allocation. They will decide whether or not a
primary end-point has occurred and classify strokes as
thrombo-embolic, haemorrhagic, or uncertain.
A variety of secondary outcome measures are assessed dur-
ing the GP follow-ups, researcher case note review and the
annual patient questionnaire (table 3). Key secondary
outcomes include: major extra-cranial haemorrhage
(defined as a fatal haemorrhage, or one that requires
transfusion or surgery); all stroke (including non-disa-
bling stroke); vascular deaths; all deaths; and vascular
admissions (including myocardial infarction and
pulmonary embolus). Since the GPs providing clinical
care are unblinded, pulse and blood pressure are being
monitored to reflect any possible differential treatment in
the two groups (for example, better treatment of hyperten-
sion or heart failure). Key secondary events (deaths, extra-
cranial major haemorrhage; vascular admissions) will be
reviewed by an independent clinician blinded to treat-
ment allocation to ensure unbiased coding of these
events.
Sample size considerations
Randomisation of 1240 patients (620 in each arm), with
an average of three years follow-up, will detect a 33%
reduction in the relative risk of acute stroke (ischaemic or
haemorrhagic) or arterial embolus between groups with
90% power (alpha = 0.05). This figure assumes that the
annual incidence of the primary end-point on aspirin is
9%,[6,16] the annual rate of primary end-points or death
will be 14% and that loss to follow up will be 1%.
To recruit 1240 patients from primary care, an estimate of
the number of practices is needed. It was assumed that 7%
of the general population are aged 75 years or over and
about 9% of this age range will be in AF [4]. Of these, 35%
might be expected to have a contra-indication to warfarin
[27] and 17% have an indication for warfarin [30]. This
suggests that 48% of patients identified as being in AF will
be eligible to enter the trial. If 75% of eligible patients are
identified, and 50% of these agree to enter the trial, this
would result in a recruitment rate of 113 per 100,000
practice population. Therefore, to recruit 1240 patients a
total practice population of 1,097,000 is required com-
prising 76,800 aged 75 years or over. This equates to 157
practices with an average list size of 7,000 and recruitment
of eight patients per practice.
Statistical analysis
The primary analysis will be a comparison of warfarin
with aspirin for prevention of the primary end-point fol-
lowing the "intention to treat" principle. Intention to treat
analyses will also be performed for the secondary out-
comes. Analyses of primary and secondary endpoints,
comparing time to event in the two arms, will be per-
formed using the log rank method. Cox regression will
also be carried out. All significance tests will be two-sided.
Pre-planned sub-group analysis will be performed for the
following sub-groups: age (75–79, 80–84, 85+ years) and
gender; method of identification of AF (opportunistic
screening/computer search identified); history of prior
stroke or transient ischaemic attack (yes/no); on warfarin
prior to study entry (yes/no); and study ECG showing
atrial fibrillation or sinus rhythm (as pragmatic distinc-
tion between permanent and paroxysmal atrial fibrilla-
tion). A secondary on-treatment analysis will be
performed to explore the risks of major haemorrhage. We
will also explore the possible effects of other patient char-
acteristics such as blood pressure and concomitant use of
other nonsteroidals.
Economic evaluation
The economic evaluation will adopt a broad perspective,
including costs incurred within the health sector and by
patients and carers. Data collection will be undertaken on
all trial patients in order to allow a stochastic cost analysis
to be conducted. The focus of the data collection will be
upon the key cost drivers which will include: drug and
INR monitoring, contacts with secondary care; primary
care visits. The analysis will adopt an incremental
approach such that data collection will concentrate on
resource use differences between trial arms. The process of
collecting data on resource use will be undertaken sepa-
rately from data collection on unit costs. Resource use
data will principally be collected within the trial. Unit
costs will be collected from published sources and a rep-
resentative sample of NHS providers in order to increase
generalisability. The methods to be used in collecting data
will include a review of patient records (both GP and hos-
pital), whilst private costs data will be collected from a
survey of a sub-cohort of the trial population.
Plan of analysis
It is not possible to state with certainty at the outset which
form of economic analysis will be employed, since this
will be driven in part by the trial results. The plan for the
analysis is to report a cost consequence analysis, which
will involve providing a full description of all important
results relating to costs and consequences. If no differ-
ences in consequences are observed, then a cost minimi-
sation analysis will be conducted. If differences in
consequences are observed, then a cost utility analysis will
be conducted using data on EQ-5D [38] to estimate Qual-BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/9
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ity Adjusted Life Years. Whichever form of analysis is
employed, an incremental approach will be used. To pre-
dict overall programme costs, the mean costs per patient
will be compared using either parametric or non-paramet-
ric methods depending on the distribution of the data
[39].
Longer term costs and consequences will be explored by
extrapolating beyond the end of the trial using a model-
ling framework. The precise form of modelling is yet to be
determined, but is likely to be either Markov or Discrete
Event Simulation, depending upon the extent to which
the Markov assumptions are justified. An advantage of
using such an approach is that it will allow the additional
costs of increasing survival to be explicitly incorporated
into the analysis.
The robustness of the results of the economic analysis will
be explored using sensitivity analysis. This will explore
uncertainties in the trial based data itself, the methods
employed to analyse the data and the generalisability of
the results to other settings. Uncertainty in the confidence
to be placed on the results of the economic analysis will
be explored by estimating cost-effectiveness acceptability
curves. These plot the probability that the intervention is
cost-effective against threshold values for cost-effective-
ness.
Time plan for the BAFTA study
Patient recruitment began in April 2001 and is planned to
continue until December 2004. By August 2003, 382
patients (31% of target) have been recruited into the trial.
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